Fgf21 variants

Abstract

The present invention relates to polypeptide variants of human fibroblast growth factor 21 (FGF21) and fusion molecules thereof, as well as to nucleic acid molecules encoding the same. It further relates to their use as medicaments, in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes mellitus, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and/or atherosclerosis.

1 . A variant of human fibroblast growth factor 21 (FGF21) comprising the amino acid sequence of SEQ ID NO: 171, 
       wherein
 Xaa55 is Q or C; 
 Xaa147 is P or C; 
 Xaa148 is G or C; 
 Xaa149 is N or C; 
 Xaa150 is K; 
 Xaa151 is S; 
 Xaa152 is P; 
 Xaa153 is H; 
 Xaa154 is R; 
 Xaa155 is D or C; 
 Xaa156 is P; 
 Xaa157 is A; 
 Xaa158 is P; 
 Xaa159 is R; 
 Xaa160 is G ; 
 Xaa161 is P or C; 
 Xaa162 is A or C; 
 Xaa163 is R; 
 Xaa184 is Q; 
 Xaa185 is P; 
 Xaa186 is P; 
 Xaa187 is D; 
 Xaa188 is V; 
 Xaa189 is G; 
 Xaa190 is S; 
 Xaa191 is S; 
 Xaa192 is D; 
 Xaa193 is P; 
 Xaa194 is L; 
 aa195 is S or C; 
 Xaa196 is M or another amino acid, such as P, V or C, or deleted; 
 Xaa197 is V or another amino acid, such as E, D, G or M, or deleted; 
 Xaa198 is G or another amino acid, such as E, D, R, K, Y, P or V, or deleted; 
 Xaa199 is P or another amino acid, such as S, Q, R, T, G, F, L, D or M, or deleted; 
 Xaa200 is S or another amino acid, such as Q, M, C, P, N or H, or deleted; 
 Xaa201 is Q or another amino acid, such as P or S, or deleted; 
 Xaa202 is G or another amino acid, such as T, or deleted; 
 Xaa203 is R or another amino acid, such as E, H or C, or deleted; 
 Xaa204 is S; 
 aa205 is P; 
 Xaa206 is S; and 
 Xaa207 is Y; 
 
       wherein, optionally, SEQ ID NO: 171 comprises a substitution of at least one of the following amino acids with C: R47, L49, T51, A54, Q56, A59, H60, E62, I63, G67, V69, G71, A72, A73, S76, P77, E78, S79, L80, L81, Q82, L83, I91, L94, G95, V96, K97, T98, R100, L102, Q104, D107, G108, L110, G112, L114, A120, R124, D130, Y132, Q136, 5137, A139, H140, L142, P143, H145, L146, L165, L167, L170, P174; 
       with the proviso that SEQ ID NO: 171 is not mature human wild-type FGF21 (SEQ ID NO: 2) and comprises 0, 2, 4, 6 or 8 additional cysteines as compared to mature human wild-type FGF21 (SEQ ID NO: 2), wherein, optionally, SEQ ID NO: 171 further comprises the mutation G141S and/or the mutation P174L. 
     
     
         2 . The variant according to  claim 1  comprising the amino acid sequence of SEQ ID NO: 175. 
     
     
         3 . The variant according to  claim 1 , wherein
 Xaa197 to Xaa203 are deleted and replaced by a protease resistant peptide linker, such as selected from SEQ ID NO: 166 and SEQ ID NO: 167;   a protease resistant peptide linker, such as SEQ ID NO: 168, is inserted between Xaa198 and Xaa199; and/or   the amino acid sequence of SEQ ID NO: 169 or SEQ ID NO: 170 is added after S209 of SEQ ID NO: 171.   
     
     
         4 . The variant according to  claim 1 , wherein SEQ ID NO: 171 has at least 90% or at least 91% or at least 92% or at least 93% or at least 94% or at least 95% or at least 96% or at least 97% or at least 98% sequence identity with mature human wild-type FGF21 (SEQ ID NO: 2). 
     
     
         5 . The variant according to  claim 1 , wherein
 Xaa161 is P;   Xaa162 is A;   Xaa195 is S;   Xaa196 is M;   Xaa197 is V;   Xaa200 is S;   Xaa201 is Q;   Xaa202 is G; and   Xaa203 is R;   
       wherein, optionally, SEQ ID NO: 171 comprises a substitution of at least one of the following amino acids with C: R47, A59, H60, G71, S76, S79, D107, G108, L142, P174. 
     
     
         6 . The variant according to  claim 5  comprising the amino acid sequence of SEQ ID NO: 176. 
     
     
         7 . The variant according to  claim 1 , wherein SEQ ID NO: 171 comprises a substitution of the following amino acids with C:
 Xaa55 and Xaa149;   R47 and P174;   Xaa55 and Xaa147;   A59 and G71;   H60 and S79;   S76 and S79;   D107 and Xaa155; and/or   G108 and L142.   
     
     
         8 . The variant according to claim , wherein
 Xaa55 is C, Xaa147 is C, Xaa149 is N, Xaa155 is D, Xaa198 is G, and Xaa199 is deleted;   Xaa55 is C, Xaa147 is C, Xaa149 is N, Xaa155 is D, Xaa198 is Y, and Xaa199 is P;   Xaa55 is C, Xaa147 is P, Xaa149 is C, Xaa155 is D, Xaa198 is G, and Xaa199 is deleted;   Xaa55 is C, Xaa147 is P, Xaa149 is C, Xaa155 is D, Xaa198 is Y, and Xaa199 is P;   Xaa55 is Q, Xaa147 is P, Xaa149 is N, Xaa155 is D, Xaa198 is G, and Xaa199 is deleted;   Xaa55 is Q, Xaa147 is P, Xaa149 is N, Xaa155 is D, Xaa198 is R, and Xaa199 is P;   Xaa55 is Q, Xaa147 is P, Xaa149 is N, Xaa155 is D, Xaa198 is K, and Xaa199 is P;   Xaa55 is Q, Xaa147 is P, Xaa149 is N, Xaa155 is D, Xaa198 is Y, and Xaa199 is P;   Xaa55 is C, Xaa147 is C, Xaa149 is N, Xaa155 is D, Xaa198 is G, and Xaa199 is P;   Xaa55 is C, Xaa147 is P, Xaa149 is C, Xaa155 is D, Xaa198 is G, and Xaa199 is P;   Xaa55 is Q, Xaa147 is P, Xaa149 is N, Xaa155 is D, Xaa198 is G, and Xaa199 is deleted, wherein SEQ ID NO: 171 comprises the substitution of A59 and G71 with C;   Xaa55 is Q, Xaa147 is P, Xaa149 is N, Xaa155 is D, Xaa198 is Y, and Xaa199 is P, wherein SEQ ID NO: 171 comprises the substitution of A59 and G71 with C;   Xaa55 is Q, Xaa147 is P, Xaa149 is N, Xaa155 is D, Xaa198 is G, and Xaa199 is deleted, wherein SEQ ID NO: 171 comprises the substitution of S76 and S79 with C;   Xaa55 is Q, Xaa147 is P, Xaa149 is N, Xaa155 is D, Xaa198 is Y, and Xaa199 is P, wherein SEQ ID NO: 171 comprises the substitution of S76 and S79 with C;   Xaa55 is Q, Xaa147 is P, Xaa149 is N, Xaa155 is D, Xaa198 is G, and Xaa199 is deleted, wherein SEQ ID NO: 171 comprises the substitution of G108 and L142 with C;   Xaa55 is Q, Xaa147 is P, Xaa149 is N, Xaa155 is D, Xaa198 is Y, and Xaa199 is P, wherein SEQ ID NO: 171 comprises the substitution of G108 and L142 with C;   Xaa55 is Q, Xaa147 is P, Xaa149 is N, Xaa155 is C, Xaa198 is G, and Xaa199 is deleted, wherein SEQ ID NO: 171 comprises the substitution of D107 with C; or   
       Xaa55 is Q, Xaa147 is P, Xaa149 is N, Xaa155 is C, Xaa198 is Y, and Xaa199 is P, wherein SEQ ID NO: 171 comprises the substitution of D107 with C. 
     
     
         9 . The variant according to  claim 1 , further comprising at least one additional amino acid at its N-terminus. 
     
     
         10 . (canceled) 
     
     
         11 . A variant of human fibroblast growth factor 21 (FGF21) comprising or consisting of an amino acid sequence according to one of SEQ ID NOs: 269, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 61, 62, 63, 64, 69, 70, 71, 72, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 153, 154, 155, 156, 157, 158, 159 160, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 230, 231, 232, 233, 238, 239, 240, 241, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 268, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 322, 323, 324, 325, 326, 327 and 328, wherein, optionally, the variant further comprises the mutation G141S and/or the mutation P174L, wherein the numbering of the amino acids is in accordance with SEQ ID NO: 1. 
     
     
         12 . The variant according to  claim 1 , wherein the variant has an increased proteolytic stability in human and/or murine blood plasma as compared to mature human wild-type FGF21 (SEQ ID NO: 2). 
     
     
         13 . The variant according to  claim 1 , wherein the variant has an increased thermal stability as compared to mature human wild-type FGF21 (SEQ ID NO: 2). 
     
     
         14 . The variant according to  claim 1 , wherein the variant induces phosphorylation of the mitogen-activated protein kinase (MAPK) ERK1/2. 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . The variant according to  claim 1 , being fused or conjugated to a half-life extension module, wherein the half-life extension module is selected from the group consisting of a polymer, an unstructured (poly-)peptide chain, an elastin-lik polypeptide (ELP), a serum protein, a serum protein binding molecule, an antibody, an immunoglobulin, an Fc region/domain of an immunoglobulin and an immunoglobulin binding domain. 
     
     
         18 . (canceled) 
     
     
         19 . A fusion molecule comprising a variant of human FGF21 according to  claim 1  and at least one other active pharmaceutical ingredient. 
     
     
         20 . A nucleic acid molecule encoding a variant of human FGF21 according to  claim 1 . 
     
     
         21 . (canceled) 
     
     
         22 . A host cell containing a nucleic acid molecule according to  claim 20 . 
     
     
         23 . A method of producing a variant of human FGF21 comprising cultivating a host cell according to  claim 22  and isolating the variant or fusion molecule from the culture medium. 
     
     
         24 . A pharmaceutical composition comprising a variant of human FGF21 according to  claim 1 , together with a pharmaceutically acceptable carrier and/or excipient. 
     
     
         25 . (canceled) 
     
     
         26 . The fusion molecule according to  claim 19 . wherein the at least one other active pharmaceutical ingredient is selected from the group consisting of insulin and insulin derivatives, GLP-1, GLP-1 analogues and GLP-1 receptor agonists, polymer bound GLP-1 and GLP-1 analogues, dual GLP-1/GIP agonists, dual GLP-1/glucagon receptor agonists, PYY3-36 or analogues thereof, pancreatic polypeptide or analogues thereof, glucagon receptor agonists or antagonists, GIP receptor agonists or antagonists, ghrelin antagonists or inverse agonists, xenin and analogues thereof, DDP-IV inhibitors, SGLT-2 inhibitors, dual SGLT-2/SGLT-1 inhibitors, biguanides, thiazolidinediones, PPAR agonists, PPAR modulators, sulfonylureas, meglitinides, alpha-glucosidase inhibitors, amylin and amylin analogues, GPR119 agonists, GPR40 agonists, GPR120 agonists, GPR142 agonists, TGRS agonists, AMPK stimulants, AMPK activators, inhibitors of 11-beta-HSD, activators of glucokinase, inhibitors of DGAT, inhibitors of protein tyrosine phosphatase 1, inhibitors of glucose-6-phosphatase, inhibitors of fructose-1,6-bisphosphatase, inhibitors of glycogen phosphorylase, inhibitors of phosphoenol pyruvate carboxykinase, inhibitors of glycogen synthase kinase, inhibitors of pyruvate dehydrogenase kinase, CCR-2 antagonists, modulators of glucose transporter-4, somatostatin receptor 3 agonists, HMG-CoA-reductase inhibitors, fibrates, nicotinic acid and derivatives thereof, nicotinic acid receptor 1 agonists, ACAT inhibitors, cholesterol absorption inhibitors, bile acid-binding substances, IBAT inhibitors, MTP inhibitors, modulators of PCSK9, LDL receptor up-regulators (liver selective thyroid hormone receptor beta agonists), HDL-raising compounds, lipid metabolism modulators, PLA2 inhibitors, ApoA-I enhancers, cholesterol synthesis inhibitors, omega-3 fatty acids and derivatives thereof, active substances for the treatment of obesity, CB1 receptor antagonists, MCH-1 antagonists, MC4 receptor agonists and partial agonists, NPYS or NPY2 antagonists, NPY4 agonists, beta-3 adrenergic receptor agonists, leptin or leptin mimetics, 5HT2c receptor agonists, lipase inhibitors, angiogenesis inhibitors, H3 antagonists, AgRP inhibitors, triple monoamine uptake inhibitors, MetAP2 inhibitors, antisense oligonucleotides against production of fibroblast growth factor receptor 4 or prohibitin targeting peptide-1, drugs for influencing high blood pressure, chronic heart failure or atherosclerosis, angiotensin II receptor antagonists, dual angiotensin receptor blockers (ARB), angiotensin converting enzyme (ACE) inhibitors, angiotensin converting enzyme 2 (ACE-2) activators, renin inhibitors, prorenin inhibitors, endothelin converting enzyme (ECE) inhibitors, endothelin receptor blockers, endothelin antagonists, diuretics, aldosterone antagonists, aldosterone synthase inhibitors, alpha-blockers, antagonists of the alpha-2 adrenergic receptor, beta-blockers, mixed alpha-/beta-blockers, calcium antagonists/calcium channel blockers (CBBs), dual mineralocorticoid/CCB s, centrally acting antihypertensives, inhibitors of neutral endopeptidase, aminopeptidase-A inhibitors, vasopeptide inhibitors, dual vasopeptide inhibitors, neprilysin-ACE inhibitors, neprilysin-ECE inhibitors, dual-acting Angiotensin (AT) receptor-neprilysin inhibitors, dual AT1/endothelin-1 (ETA) antagonists, advanced glycation end-product breakers, recombinant renalase, blood pressure vaccines, anti-RAAS vaccines, AT1- or AT2-vaccines, modulators of genetic polymorphisms with antihypertensive response and thrombocyte aggregation inhibitors. 
     
     
         27 - 30 . (canceled) 
     
     
         31 . A method of treating a disease or disorder selected from the group consisting of obesity, overweight, metabolic syndrome, diabetes mellitus, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and atherosclerosis, the method comprising administering a variant of human FGF21 according to  claim 1  to a subject in need thereof. 
     
     
         32 . (canceled)